Home/Filings/4/0001193125-25-253873
4//SEC Filing

Gao Hanlin 4

Accession 0001193125-25-253873

CIK 0001674930other

Filed

Oct 27, 8:00 PM ET

Accepted

Oct 28, 5:20 PM ET

Size

5.0 KB

Accession

0001193125-25-253873

Insider Transaction Report

Form 4
Period: 2025-10-26
Gao Hanlin
Chief Scientific Officer
Transactions
  • Tax Payment

    Common Stock

    2025-10-26$23.74/sh1,642$38,981955,443 total
Footnotes (1)
  • [F1]The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

Documents

1 file

Issuer

Fulgent Genetics, Inc.

CIK 0001674930

Entity typeother

Related Parties

1
  • filerCIK 0001684532

Filing Metadata

Form type
4
Filed
Oct 27, 8:00 PM ET
Accepted
Oct 28, 5:20 PM ET
Size
5.0 KB